Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hyalolex (IGC-AD1) / IGC Pharma
IGC-AD1-P2, NCT05543681: Clinical Trial on Agitation in Alzheimer's Dementia	Recruiting	2	164	Canada, US, RoW	IGC-AD1-Active, Active, IGC-AD1-Placebo, Placebo	IGC Pharma, LLC	Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression	06/25	06/25
PP-01 / PleoPharma
NCT05494437: Effect of PP-01 on Cannabis Withdrawal Syndrome	Completed	2	234	US	PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin	PleoPharma, Inc.	Cannabis Withdrawal	08/23	08/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hyalolex (IGC-AD1) / IGC Pharma
IGC-AD1-P2, NCT05543681: Clinical Trial on Agitation in Alzheimer's Dementia	Recruiting	2	164	Canada, US, RoW	IGC-AD1-Active, Active, IGC-AD1-Placebo, Placebo	IGC Pharma, LLC	Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression	06/25	06/25
PP-01 / PleoPharma
NCT05494437: Effect of PP-01 on Cannabis Withdrawal Syndrome	Completed	2	234	US	PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin	PleoPharma, Inc.	Cannabis Withdrawal	08/23	08/23